ANI Pharmaceuticals (ANIP) Set to Announce Earnings on Friday

ANI Pharmaceuticals (NASDAQ:ANIP) is scheduled to announce its earnings results before the market opens on Friday, November 8th. Analysts expect the company to announce earnings of $1.09 per share for the quarter. ANI Pharmaceuticals has set its FY24 guidance at $4.38-4.82 EPS and its FY 2024 guidance at 4.380-4.820 EPS.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.95 by $0.07. ANI Pharmaceuticals had a net margin of 5.01% and a return on equity of 15.64%. The firm had revenue of $138.00 million during the quarter, compared to analysts’ expectations of $129.09 million. During the same period last year, the business earned $1.06 earnings per share. ANI Pharmaceuticals’s revenue was up 18.5% compared to the same quarter last year. On average, analysts expect ANI Pharmaceuticals to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

ANI Pharmaceuticals Price Performance

Shares of ANIP opened at $57.25 on Friday. ANI Pharmaceuticals has a 1-year low of $48.20 and a 1-year high of $70.81. The stock has a market cap of $1.20 billion, a PE ratio of 48.92 and a beta of 0.71. The firm has a 50-day simple moving average of $59.27 and a two-hundred day simple moving average of $61.88. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.97 and a quick ratio of 3.07.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on ANIP shares. Truist Financial lifted their price target on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a research report on Tuesday, October 22nd. HC Wainwright reiterated a “buy” rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a research report on Tuesday, September 17th. Piper Sandler started coverage on shares of ANI Pharmaceuticals in a research report on Friday, October 11th. They set an “overweight” rating and a $68.00 price target for the company. StockNews.com cut shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, September 7th. Finally, Raymond James lifted their price target on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an “outperform” rating in a research report on Wednesday, September 18th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, ANI Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $77.33.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.